Activity of lipopolysaccharide-binding protein-bactericidal/permeability-increasing protein fusion peptide in an experimental model of Pseudomonas sepsis.

Antimicrobial Agents and Chemotherapy
S M OpalM N Marra

Abstract

A chimeric protein consisting of the N-terminal domain of lipopolysaccharide-binding protein and the C-terminal domain of bactericidal/permeability-increasing protein demonstrated a dose-dependent survival benefit (P = 0.001) and reduced endotoxin levels (P < 0.01) in neutropenic rats with Pseudomonas aeruginosa sepsis. This lipopolysaccharide-binding protein-bactericidal/ permeability-increasing peptide has favorable pharmacokinetics and antiendotoxin properties which may be of value for human sepsis.

References

Sep 15, 1991·Annals of Internal Medicine·R C Bone
Sep 21, 1990·Science·R R SchumannR J Ulevitch

❮ Previous
Next ❯

Citations

May 6, 1998·Protein Science : a Publication of the Protein Society·L J BeamerD Eisenberg
Jun 19, 2021·Journal of Translational Autoimmunity·Jomkuan TheprungsirikulWilliam F C Rigby

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.